TOKYO--(BUSINESS WIRE)--Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo. The study was presented at the Plenary General Session of International Liver Cancer Association Fourth Annual Conference (ILCA2010) on September 11, 2010 (Presentation number O-014). Kowa plans to submit peretinoin to regulatory authorities in Japan for marketing authorization.
